Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Daiichi Sankyo
Queensland Health
Cerilliant
Fish and Richardson
Fuji
Moodys
Cantor Fitzgerald
Julphar

Generated: May 23, 2018

DrugPatentWatch Database Preview

SUCRAID Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Sucraid, and what generic alternatives are available?

Sucraid is a drug marketed by Qol Medcl and is included in one NDA. There is one patent protecting this drug.

This drug has three patent family members in three countries.

The generic ingredient in SUCRAID is sacrosidase. One supplier is listed for this compound. Additional details are available on the sacrosidase profile page.
Summary for SUCRAID
International Patents:3
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 1
DailyMed Link:SUCRAID at DailyMed
Drug patent expirations by year for SUCRAID
Pharmacology for SUCRAID

US Patents and Regulatory Information for SUCRAID

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Qol Medcl SUCRAID sacrosidase SOLUTION;ORAL 020772-001 Apr 9, 1998 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Non-Orange Book US Patents for SUCRAID

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,255,261 Ultrapure hypoallergenic solutions of sacrosidase ➤ Try a Free Trial
9,849,161 Ultrapure hypoallergenic solutions of sacrosidase ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Dow
Covington
Chinese Patent Office
US Department of Justice
Baxter
Cipla
Federal Trade Commission
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.